LACK OF EFFECT OF TACRINE ADMINISTRATION ON THE ANTICOAGULANT ACTIVITY OF WARFARIN

被引：2

作者：

REECE, PA

GARNETT, WR

ROCK, WL

TAYLOR, JR

UNDERWOOD, B

SEDMAN, AJ

RAJAGOPALAN, R

机构：

[1] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CLIN PHARMACOL,ANN ARBOR,MI 48106

[2] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT BIOMETR,ANN ARBOR,MI 48106

[3] VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298

[4] BIOCLIN CORP,RICHMOND,VA

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 1995年 / 35卷 / 05期

关键词：

D O I：

10.1002/j.1552-4604.1995.tb04099.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effect of tacrine administration on prothrombin time was studied in 13 patients receiving prolonged warfarin therapy. After a 3-week baseline period and 5 days of placebo administration, patients received 20 mg tacrine four rimes daily for 5 days. Prothrombin times were determined during baseline, daily before the morning doses of placebo and tacrine, and 14 days after the last tacrine dose (closeout). Mean (+/- SD) prothrombin times were 16.2 +/- 2.8 seconds at baseline, 15.1 +/- 2.6 seconds during the placebo phase, 15.8 +/- 3.6 seconds during the tacrine phase, and 15.3 +/- 3.6 seconds at closeout, indicating that tacrine has no effect on the anticoagulant activity of warfarin, Alteration of warfarin dosage should not be required in patients receiving concurrent tacrine therapy.

引用

页码：526 / 528

页数：3

共 17 条

[1]

Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, A controlled trial of tacrine in Alzheimer's disease, JAMA, 268, pp. 2523-2529, (1992)

[2]

Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR, Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain, Science, 215, pp. 1237-1239, (1986)

[3]

Waller SB, Ball MJ, Reynolds MA, London ED, Muscarinic and choline acetyltransferase in postmortem brains of demented patients, Can J Neurol Sci, 13, pp. 523-528, (1986)

[4]

Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL, Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age‐matched controls, Arch Gen Psychiatry, 44, pp. 418-426, (1987)

[5]

Davis BM, Mohs RC, Greenwald BS, Mathe AA, Johns CA, Horvath TB, Davis KL, Clinical studies of the cholinergic deficit in Alzheimer's disease. I. Neurochemical and neuroendocrine studies, J Am Geriatr Soc, 33, pp. 741-748, (1985)

[6]

Coyle JT, Price DL, DeLong MR, Alzheimer's disease: a disorder of cortical cholinergic innervation, Science, 219, pp. 1184-1190, (1983)

[7]

Reinikainen KJ, Soininen H, Riekkinen PJ, Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy, J Neurosci Res, 27, pp. 576-586, (1990)

[8]

Serlin MJ, Breckenridge AM, Drug interactions with warfarin, Drugs, 25, pp. 610-620, (1983)

[9]

Majerus PW, Broze GJ, Miletich JP, Tollefsen DM, Anticoagulant, thrombolytic, and antiplatelet drugs, Goodman and Gilman's The Pharmacological Basis of Therapeutics, pp. 1311-1331, (1990)

[10]

Hansten PD, Drug Interactions, (1985)

← 1 2 →